跳至主要内容
临床试验/NCT03633266
NCT03633266Unknown不适用

Feasibility Study of Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy

Wenzhou Medical University0 个研究点目标入组 220 人开始时间: 2018年9月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
220
主要终点
Mean change from baseline in best-corrected visual acuity (BCVA)

研究概览

简要总结

To evaluate the efficacy and safety of vitreoretinal surgery combined with anti-VEGF therapy in the replacement of intraoperative PRP in PDR therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age≥18 years old;
  • type 1 or type 2 diabetes.
  • proliferative diabetic retinopathy with vitreous hemorrhage, and conservative treatment of vitreous hemorrhage without obvious absorption for 1 month requires vitreoretinal surgery;
  • The postoperative refractive medium is clear and the pupil is large enough to obtain sufficient clear fundus

排除标准

  • Previously received panretinal photocoagulation or unfinished panretinal photocoagulation;
  • Pulling retinal detachment involving the macula or the presence of extensive fiber proliferation requires silicone oil filling;
  • anterior chamber neovascularization or neovascular glaucoma;
  • other vascular diseases such as retinal vein occlusion, arterial occlusion, etc;
  • received intraocular anti-VEGF therapy or triamcinolone acetonide treatment which are still in the treatment period.

结局指标

主要结局

Mean change from baseline in best-corrected visual acuity (BCVA)

时间窗: 3 years

Assessed using the ETDRS protocol

次要结局

  • chang from baseline in sructure of retina(3 years)
  • Mean change from baseline in visual field(3 years)
  • chang from baseline in retinal neovascularization(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiangtian Zhou

professor

Wenzhou Medical University

相似试验